Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATEOctober
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERState University of New York, Buffalo, Buffalo, NY 14260-0001
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTThe objective of the project for the reporting period was to generate a number prostate cancer cell lines that that are either myosin IC isoform A deficient or that constitutively express GFP-myosin IC isoform A. We used shRNA to generate isoform Anegative PC-3 cells and we generated a stable LNCaP cell line that expresses constitutively myosin IC isoform A-GFP. We are now in the process of analyzing the effect of these expression changes on secretion in these cell lines to determine the consequences of isoform A expression changes for the metastatic ability of prostate cancer cells. Using serial cloning of the 5 prime UTR of the human myosin IC gene we have identified a region that is involved in regulatory expression of myosin IC isoform A. We are now in the process of using ChIP assays to identifying the transcriptional elements that bind to this region and induce expression of myosin IC isoform A in prostate cancer cells.
SUBJECT TERMS
INTRODUCTIONWe recently discovered a previously unknown isoform of myosin IC that is called myosin IC isoform A [1]. Our data showed that this isoform is selectively expressed in prostate cancer tumors and in prostate cancer cell lines with high metastatic potential but not in normal prostate tissues or in prostate cancer cells with low metastatic potential. Class I myosins are involved in intracellular transport of vesicles that are secreted [2] and our preliminary data suggest that overexpression of myosin IC isoform A in prostate cancer cells causes an increase in secretion efficiency. Secretion is a process that is intricately linked to the acquisition of a metastatic phenotype in cancer cel...